Evidence map›Paper›PMID 25762987›Full record

ArticleFrontiers in microbiology2015

The lung mycobiome: an emerging field of the human respiratory microbiome.

Linh D N Nguyen, Eric Viscogliosi, Laurence Delhaes

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 3 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 3 syntheses or guidelines pooled it, 254 citations in OpenAlex.

  1. The Human Respiratory Microbiome: Current Understandings and Future Directions.American journal of respiratory cell and molecular biology · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Observational

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Linh D N NguyenBiology and Diversity of Emerging Eukaryotic Pathogens, Center for Infection and Immunity of Lille, INSERM U1019, CNRS UMR 8204, Lille Pasteur Institute, University of Lille Nord de France , Lille, France.
Eric ViscogliosiBiology and Diversity of Emerging Eukaryotic Pathogens, Center for Infection and Immunity of Lille, INSERM U1019, CNRS UMR 8204, Lille Pasteur Institute, University of Lille Nord de France , Lille, France.
Laurence DelhaesBiology and Diversity of Emerging Eukaryotic Pathogens, Center for Infection and Immunity of Lille, INSERM U1019, CNRS UMR 8204, Lille Pasteur Institute, University of Lille Nord de France , Lille, France ; Parasitology-Mycology Department, Hospital University Center, Faculty of Medicine , Lille, France.
Center for Infection and Immunity of Lille · FRCentre National de la Recherche Scientifique · FRUniversité Lille Nord de France · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lung microbiome, which is believed to be stable or at least transient in healthy people, is now considered as a poly-microorganism component contributing to disease pathogenesis. Most research studies on the respiratory microbiome have focused on bacteria and their impact on lung health, but there is evidence that other non-bacterial organisms, comprising the viruses (virome) and fungi (mycobiome), are also likely to play an important role in healthy people as well as in patients. In the last few years, the lung mycobiome (previously named the fungal microbiota or microbiome) has drawn closer attention. There is growing evidence that the lung mycobiome has a significant impact on clinical outcome of chronic respiratory diseases (CRD) such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, and bronchiectasis. Thanks to advances in culture independent methods, especially next generation sequencing, a number of fungi not detected by culture methods have been molecularly identified in human lungs. It has been shown that the structure and diversity of the lung mycobiome vary in different populations (healthy and different diseased individuals) which could play a role in CRD. Moreover, the link between lung mycobiome and different biomes of other body sites, especially the gut, has also been unraveled. By interacting with the bacteriome and/or virome, the respiratory mycobiome appears to be a cofactor in inflammation and in the host immune response, and therefore may contribute to the decline of the lung function and the disease progression. In this review, we report the recent limited explorations of the human respiratory mycobiome, and discuss the mycobiome's connections with other local microbial communities, as well as the relationships with the different biomes of other body sites. These studies suggest several outlooks for this understudied emerging field, which will certainly call for a renewal of our understanding of pulmonary diseases.

Indexed as

chronic respiratory diseasefungal microbiotalungmicrobiomemycobiotarespiratory mycobiome

Identifiers

PMID25762987
PMCPMC4327734
OpenAlexW2172064173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.